Imeik Investment Quality Review (300896.SZ)

Quality score: 85/100 Valuation position: current price/base FV 1.45 Final signal: WATCHLIST

Core Conclusion

Imeik is WATCHLIST. The business scores very well, but current price of CNY104.46 is above conservative/base FV of CNY43.65/CNY72.04. Quality alone does not overcome the valuation gap.

Business And Quality

Five-year revenue CAGR is 14.1% and latest-year FCF is CNY1.15bn. The 85/100 score reflects strong economics and net cash, while product-cycle, regulatory, and evidence-depth checks prevent a higher signal at this price.

Financial Audit

The review uses fiscal 2021-2025 in CNY. Five-year average FCF/Net Income is 0.91 and OCF/Net Income is 1.00. Latest net cash is CNY0.97bn. Market value is about CNY31.61bn on roughly 303mn shares.

Valuation

The valuation uses normalized FCF, a 1.7% CNY 10Y yield dated 2026-07-27, and separate balance-sheet adjustments. Price/base FV of 1.45 does not satisfy the margin-of-safety or 2x gates.

Buy And Monitor

Current action is watchlist. Upgrade requires price/base FV below 0.70, quality score at least 75, and stronger evidence that growth and FCF are durable. Track revenue trend, FCF/Net Income, ROIC, net cash/debt, dividends, buybacks, and governance disclosure.

Risks

Risks include product concentration, medical-aesthetics regulation, competition, weaker cash conversion, and shareholder returns that do not improve per-share value. Sustained FCF/Net Income below 0.60 would reduce FV.

Sources

Sources are public quote and financial data platforms, official filings or company IR, and ChinaBond for the CNY risk-free rate. Research only, not personalized investment advice.